Immunopathogenesis and target therapy of Alzheimer’s disease

Abstract

Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases in the elderly worldwide. However the ambiguity of the development and causal factors of AD leads to a discrepancy in the understanding of the pathogenesis of the disease and may be one of the reason for the complexity of the development of drugs for AD. The review presents new data on the conduct of clinical trials treatment methods that affect the pathophysiological processes in AD. Targeted drugs aimed at neuroinflammation induced by NLRP3 inflammasome, monoclonal antibodies and drugs for active immunization against beta amyloid, tau protein are considered.